---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-102293"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-09-20T23:59:59+00:00"
generated_at: "2026-06-10T11:42:16.933961+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Eloxx Pharmaceuticals raises ~$2M in registered direct offering and private placement

## Summary
- Sold 305,590 shares + 75,000 pre-funded warrants at ~$5.255/unit, and 380,590 private warrants at $5.13 exercise.
- Gross proceeds approximately $2.0M; H.C. Wainwright placement agent with 7.5% fee and 22,835 warrant shares.
- Private and placement warrants issued unregistered under Section 4(a)(2) exemption.
- Pre-funded warrant exercise price $0.001; private warrant term 5.5 years; both have beneficial ownership caps.
- Proceeds intended for general corporate purposes.

## SEC filing metadata
- accession: 0001104659-23-102293
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-09-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923102293/0001104659-23-102293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923102293/tm2326470d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-102293
- JSON: https://secwatch.observer/filing/0001104659-23-102293.json
- Plain text: https://secwatch.observer/filing/0001104659-23-102293.txt

## Key facts
- Material Agreements
  Eloxx Pharmaceuticals, Inc. entered into Purchase Agreement with a certain institutional investor (effective 2023-09-18).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a certain institutional investor
  - Effective: 2023-09-18
  source text: On September 18, 2023, Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923102293/0001104659-23-102293-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.